{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:19:45Z","timestamp":1792271985686,"version":"4.4.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,12,13]],"date-time":"2011-12-13T00:00:00Z","timestamp":1323734400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s00415-011-6339-8","type":"journal-article","created":{"date-parts":[[2011,12,12]],"date-time":"2011-12-12T15:12:37Z","timestamp":1323702757000},"page":"1215-1221","source":"Crossref","is-referenced-by-count":18,"title":["Effect of natalizumab on clinical and radiological disease activity in a French cohort of patients with relapsing-remitting multiple sclerosis"],"prefix":"10.1007","volume":"259","author":[{"given":"A.","family":"Melin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Outteryck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Collongues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Z\u00e9phir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. C.","family":"Fleury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lacour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. C.","family":"Ongagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. S.","family":"Berteloot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Vermersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"S\u00e8ze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,12,13]]},"reference":[{"key":"6339_CR1","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899\u2013910","journal-title":"N Engl J Med"},{"key":"6339_CR2","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1474-4422(09)70021-3","volume":"8","author":"E Havrdova","year":"2009","unstructured":"Havrdova E, Galetta S, Hutchinson M et al (2009) Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the natalizumab safety and efficacy in relapsing-remitting multiple sclerosis (AFFIRM) study. Lancet Neurol 8:254\u2013260","journal-title":"Lancet Neurol"},{"key":"6339_CR3","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1212\/01.wnl.0000277457.17420.b5","volume":"69","author":"PA Calabresi","year":"2007","unstructured":"Calabresi PA, Giovannoni G, Confavreux C et al (2007) The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 69:1391\u20131403","journal-title":"Neurology"},{"issue":"Suppl 3","key":"6339_CR4","first-page":"S303","volume":"31","author":"L Prosperini","year":"2010","unstructured":"Prosperini L, Borriello G, Fubelli F et al (2010) Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome. Neurol Sci 31(Suppl 3):S303\u2013S307","journal-title":"Neurol Sci"},{"key":"6339_CR5","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/1352458510385507","volume":"17","author":"O Fernandez","year":"2011","unstructured":"Fernandez O, Papais Alvarenga O, Guerrero M et al (2011) The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study. Mult Scler 17:192\u2013197","journal-title":"Mult Scler"},{"issue":"Suppl 3","key":"6339_CR6","doi-asserted-by":"crossref","first-page":"S295","DOI":"10.1007\/s10072-010-0356-8","volume":"31","author":"GL Mancardi","year":"2011","unstructured":"Mancardi GL, Tedeschi G, Amato MP et al (2011) Three years of experience: the Italian registry and safety data update. Neurol Sci 31(Suppl 3):S295\u2013S297","journal-title":"Neurol Sci"},{"issue":"Suppl 3","key":"6339_CR7","doi-asserted-by":"crossref","first-page":"S289","DOI":"10.1007\/s10072-010-0345-y","volume":"31","author":"F Piehl","year":"2011","unstructured":"Piehl F, Holmen C, Hillert J et al (2011) Swedish natalizumab (Tysabri) multiple sclerosis surveillance study. Neurol Sci 31(Suppl 3):S289\u2013S293","journal-title":"Neurol Sci"},{"issue":"Suppl 3","key":"6339_CR8","doi-asserted-by":"crossref","first-page":"S299","DOI":"10.1007\/s10072-010-0344-z","volume":"31","author":"F Sangalli","year":"2011","unstructured":"Sangalli F, Moiola L, Bucello S et al (2011) Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post marketing observational study. Neurol Sci 31(Suppl 3):S299\u2013S302","journal-title":"Neurol Sci"},{"key":"6339_CR9","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1177\/1352458510394701","volume":"17","author":"C Holmen","year":"2011","unstructured":"Holmen C, Piehl F, Hillert J et al (2011) A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler 17:708\u2013719","journal-title":"Mult Scler"},{"key":"6339_CR10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00415-009-0093-1","volume":"256","author":"M Hutchinson","year":"2009","unstructured":"Hutchinson M, Kappos L, Calabresi PA et al (2009) The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol 256:405\u2013415","journal-title":"J Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-011-6339-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-011-6339-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-011-6339-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T19:22:57Z","timestamp":1559071377000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-011-6339-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,13]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["6339"],"URL":"https:\/\/doi.org\/10.1007\/s00415-011-6339-8","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,13]]}}}